Benzodiazepine Addiction

What are benzodiazepines and how does the disorder develop?

Benzodiazepines are a class of prescription central nervous system depressants that act by enhancing the activity of GABA, the brain's primary inhibitory neurotransmitter. They produce sedation, anxiolysis, muscle relaxation, and anticonvulsant effects, which makes them clinically useful for anxiety disorders, panic disorder, insomnia, alcohol withdrawal management, and seizure control. Common prescriptions include alprazolam (Xanax), diazepam (Valium), clonazepam (Klonopin), lorazepam (Ativan), and temazepam (Restoril).

Benzodiazepine use disorder is classified under Sedative, Hypnotic, or Anxiolytic Use Disorder in the DSM-5. The diagnostic criteria are the same structure as other substance use disorders: at least two of eleven criteria over a twelve-month period. Severity ranges from mild to moderate to severe. Dependence can develop from legitimate prescription use, not only from misuse or recreational use.

Tolerance to benzodiazepines develops relatively quickly. Many people prescribed benzodiazepines for anxiety find that the original dose provides progressively less relief over weeks to months, and they either escalate the dose or augment with other substances. Physical dependence, the state in which the body requires the drug to function without withdrawal, can develop after as little as four to six weeks of daily use, particularly with higher-potency, shorter-acting benzodiazepines like alprazolam.

The pathway to benzodiazepine use disorder frequently begins legitimately. A prescription for panic attacks, generalized anxiety disorder, or insomnia, followed by a need for higher doses, a gradual realization that stopping produces severe rebound anxiety and insomnia that feels worse than the original condition. This is the tolerance and withdrawal cycle of sedative dependence, and it does not require intentional misuse to develop.

Physical and psychological signs of benzodiazepine dependence

The signs of benzodiazepine dependence are often subtler than those of opioid or stimulant use disorders, partly because the drug's primary effect is sedation rather than euphoria, and partly because it often begins with a legitimate prescription. Family members and the person themselves may attribute the changes to the underlying anxiety rather than to drug dependence.

• Needing the same prescription at a higher dose to achieve the original calming effect (tolerance)
• Using benzodiazepines more frequently or in larger amounts than prescribed
• Running out of prescriptions early and seeking refills ahead of schedule
• Seeking benzodiazepines from multiple prescribers or obtaining them from outside the medical system
• Rebound anxiety or insomnia, often more severe than the original condition, when doses are missed or the medication wears off
• Combining benzodiazepines with alcohol or opioids to enhance effect (a particularly dangerous combination)
• Sedation, slurred speech, impaired coordination, and cognitive slowing
• Memory difficulties, including anterograde amnesia (inability to form new memories during use)
• Emotional blunting, reduced motivation, and social withdrawal
• Intense anxiety, restlessness, or feeling physically unwell between doses, which drives continued use to manage withdrawal rather than for any anxiolytic benefit

Benzodiazepine withdrawal: why it can be life-threatening

Benzodiazepine withdrawal is one of two drug withdrawal syndromes, alongside alcohol withdrawal, that can cause seizures and death in people with severe dependence. This is not a theoretical risk; it is a clinical reality that must shape every conversation about stopping benzodiazepines.

The mechanism parallels alcohol withdrawal. Chronic benzodiazepine use suppresses GABA activity and the nervous system compensates by up-regulating excitatory glutamate signaling. When benzodiazepines are removed abruptly, the compensatory hyperexcitability is unmasked. The result is a state of pronounced central nervous system excitability that can manifest as anxiety, insomnia, muscle tremors, sweating, elevated heart rate and blood pressure, and in severe cases, tonic-clonic (grand mal) seizures.

The timeline of benzodiazepine withdrawal depends significantly on which benzodiazepine was used. Short-acting benzodiazepines like alprazolam (Xanax) produce withdrawal that begins within 6 to 12 hours of the last dose and can peak within 24 to 72 hours. Longer-acting benzodiazepines like diazepam (Valium) and clonazepam (Klonopin) may not produce significant withdrawal for 24 to 48 hours after the last dose, and the protracted withdrawal can last weeks.

Protracted benzodiazepine withdrawal syndrome is a recognized clinical entity in which withdrawal symptoms, particularly anxiety, insomnia, sensory disturbances, and cognitive effects, persist for months after the last dose. This is distinct from the return of the original anxiety disorder and reflects a slow normalization of GABA receptor function.

This withdrawal picture is the reason that stopping benzodiazepines abruptly at home after physical dependence has developed is medically inadvisable. The clinical standard is a medically supervised, gradual taper, typically using diazepam (the longest-acting agent) as the taper medication, reducing the dose slowly enough to allow the nervous system to recalibrate without triggering seizures. Archangel coordinates with medical partners to ensure clients who need supervised taper management have access to it before transitioning into our outpatient programs.

Treatment for benzodiazepine use disorder

There is no FDA-approved medication specifically for benzodiazepine use disorder in the way that buprenorphine is approved for opioid use disorder. The primary medical intervention is the supervised taper, typically with a longer-acting benzodiazepine such as diazepam, conducted under physician oversight to prevent seizures and manage withdrawal safely.

Following stabilization from the taper, the treatment of benzodiazepine use disorder is primarily behavioral. The same evidence-based therapies that work for other substance use disorders apply, with some emphasis on the specific issues that are prevalent in this population:

Cognitive Behavioral Therapy for anxiety (CBT-A): Most people prescribed benzodiazepines initially had a genuine anxiety disorder or panic disorder. Addressing that underlying condition with CBT, which has the strongest evidence base for anxiety disorders of any psychological treatment, is central to long-term recovery. CBT for anxiety replaces the benzodiazepine's role in managing anxiety with a durable, non-pharmacological set of skills.

Mindfulness-based approaches: Mindfulness practices, including MBSR (mindfulness-based stress reduction) and MBCT (mindfulness-based cognitive therapy), have demonstrated effectiveness for anxiety and are particularly useful in benzodiazepine recovery because they build tolerance to distress and somatic anxiety sensations.

Sleep hygiene and CBT-I (cognitive behavioral therapy for insomnia): Insomnia is a major driver of benzodiazepine use and a central withdrawal symptom. CBT-I is the first-line treatment for insomnia according to most clinical guidelines and provides lasting improvement, unlike pharmacological sleep aids.

Non-benzodiazepine anxiolytic options: Buspirone, SSRIs, SNRIs, and hydroxyzine are clinically appropriate for managing anxiety without the dependence risk of benzodiazepines. Transitioning a patient to one of these agents as part of a taper plan is a standard clinical approach. These are medical decisions made in collaboration with prescribers, not unilateral changes to medication.

The opioid-benzodiazepine combination: a critical safety issue

Combining benzodiazepines with opioids carries a specific and well-documented overdose risk that deserves explicit attention. Both drug classes are CNS depressants. When combined, they produce synergistic respiratory depression, meaning the effect on breathing is greater than either drug alone would produce. A dose of each that would not individually cause dangerous respiratory depression can, in combination, cause breathing to slow to the point of fatal hypoxia.

The FDA has issued its strongest warning, a black box warning, against the concurrent use of benzodiazepines and opioids. Despite this, polysubstance use involving both classes is common, particularly among people who are obtaining drugs outside the medical system. The combination accounts for a substantial proportion of opioid overdose deaths nationally.

In treatment contexts, this combination requires explicit clinical attention. People entering treatment for opioid use disorder who are also using benzodiazepines require careful management of both dependencies simultaneously, not treatment of one while the other continues. Archangel's clinical intake process assesses all substances in use and builds treatment plans that address the full picture.

Co-occurring mental health and benzodiazepine use disorder

Anxiety disorders, panic disorder, and insomnia are the most common co-occurring conditions in benzodiazepine use disorder, frequently predating the substance use. This creates a clinical complexity: the conditions that drove the original prescription remain to be addressed in recovery. Without treating the underlying anxiety, the pressure to return to benzodiazepine use remains very high.

Depression is also highly prevalent. Benzodiazepines produce emotional blunting during regular use, and withdrawal often unmasks or intensifies depression that was masked by the drug. Distinguishing acute protracted withdrawal from a primary depressive disorder requires time and careful observation.

Trauma histories are common and often underlie the anxiety that drove the original prescription. A trauma-informed clinical approach, one that addresses the root of the anxiety rather than only its surface-level symptoms, is essential for durable recovery. At Archangel, dual-diagnosis assessment and integrated mental health care are standard across all levels of care.

Benzodiazepine treatment in Monmouth County: The Archangel Centers

The Archangel Centers provides licensed outpatient addiction treatment for benzodiazepine use disorder at 44 Apple St STE 3, Tinton Falls, NJ. We serve Monmouth County and the Jersey Shore, coordinating with medical partners to ensure clients have access to supervised detox and taper management when needed before stepping into outpatient care.

A critical point: Archangel does not provide on-site inpatient or residential detox. Benzodiazepine dependence with significant physical withdrawal risk requires medically supervised taper before outpatient treatment can begin safely. We guide every client through accessing appropriate detox or medically managed taper, and then transition them directly into our PHP or IOP.

PHP (Partial Hospitalization Program): Intensive daily clinical programming appropriate for clients who have completed a taper or detox and require a high level of support. Group therapy, individual counseling, medication management coordination, psychoeducation including CBT for anxiety, and family support.

IOP (Intensive Outpatient Program): Three or more days per week. The core level of care for most clients following safe taper completion. Includes evidence-based group therapy, CBT, mindfulness-based approaches, relapse prevention, and individual counseling.

Standard Outpatient (OP): Weekly or twice-weekly sessions for clients in stable recovery.

Most major insurance plans and New Jersey Medicaid cover our levels of care. Insurance benefits are verified before admission.

Recovery from benzodiazepine use disorder

Recovery from benzodiazepine dependence is real and common. The path typically involves a medically supervised taper that takes weeks to months depending on the severity of dependence, followed by engagement with structured outpatient treatment to address the underlying anxiety, build non-pharmacological coping skills, and establish a recovery-supporting life structure.

Protracted withdrawal can extend the difficult period. For some clients, particularly those with long histories of high-dose benzodiazepine use, symptoms including anxiety, insomnia, and sensory disturbances can persist for months. This is a neurobiological process, not a failure of recovery or evidence that abstinence is impossible. With appropriate clinical support, the recalibration occurs and the symptoms gradually resolve.

People who achieve recovery from benzodiazepine use disorder often describe a quality of life, including the management of anxiety and sleep, that exceeds what they experienced even at the beginning of benzodiazepine use, before tolerance and dependence had developed. Genuine skill-based anxiety management through CBT and mindfulness often works better, in the long run, than pharmacological suppression.

If you or someone you love is struggling with benzodiazepine dependence in Monmouth County or along the Shore, please call before attempting to stop on your own. Our admissions team can help you understand your options, including how to access appropriate medical taper support.